User login
Key clinical point: In patients with moderate-to-severe atopic dermatitis (AD), itch was more closely associated with patient-reported outcome measures than with objective assessments by the physician.
Major finding: Itch severity had a weak positive correlation with objective Scoring Atopic Dermatitis (rho (ρ) 0.44; 95% CI 0.39-0.48), Eczema Area and Severity Index (ρ 0.41; 95% CI 0.36-0.46), and Investigator Global Assessment (ρ 0.46; 95% CI 0.42-0.51) scores, but a strong positive correlation with Patient Global Assessment score (ρ 0.68; 95% CI 0.65-0.71), Patient-Oriented Eczema Measure sum score (ρ 0.66; 95% CI 0.63-0.69), and Dermatology Life Quality Index score (ρ 0.61; 95% CI 0.57-0.65).
Study details: This study analyzed the data of 1134 adult patients with moderate-to-severe AD from the multicenter prospective TREATgermany registry, of which 1121 had provided data on their itch.
Disclosures: TREATgermany is sponsored by AbbVie Deutschland GmbH & Co. KG, Galderma S.A., and others. Some authors reported ties with various organizations, including TREATgermany sponsors.
Source: Weisshaar E et al. Itching in atopic dermatitis: Patient- and physician-reported outcomes in the German atopic dermatitis registry TREATgermany. Acta Derm Venereol. 2023;103:adv00854 (Jan 23). Doi: 10.2340/actadv.v103.4426
Key clinical point: In patients with moderate-to-severe atopic dermatitis (AD), itch was more closely associated with patient-reported outcome measures than with objective assessments by the physician.
Major finding: Itch severity had a weak positive correlation with objective Scoring Atopic Dermatitis (rho (ρ) 0.44; 95% CI 0.39-0.48), Eczema Area and Severity Index (ρ 0.41; 95% CI 0.36-0.46), and Investigator Global Assessment (ρ 0.46; 95% CI 0.42-0.51) scores, but a strong positive correlation with Patient Global Assessment score (ρ 0.68; 95% CI 0.65-0.71), Patient-Oriented Eczema Measure sum score (ρ 0.66; 95% CI 0.63-0.69), and Dermatology Life Quality Index score (ρ 0.61; 95% CI 0.57-0.65).
Study details: This study analyzed the data of 1134 adult patients with moderate-to-severe AD from the multicenter prospective TREATgermany registry, of which 1121 had provided data on their itch.
Disclosures: TREATgermany is sponsored by AbbVie Deutschland GmbH & Co. KG, Galderma S.A., and others. Some authors reported ties with various organizations, including TREATgermany sponsors.
Source: Weisshaar E et al. Itching in atopic dermatitis: Patient- and physician-reported outcomes in the German atopic dermatitis registry TREATgermany. Acta Derm Venereol. 2023;103:adv00854 (Jan 23). Doi: 10.2340/actadv.v103.4426
Key clinical point: In patients with moderate-to-severe atopic dermatitis (AD), itch was more closely associated with patient-reported outcome measures than with objective assessments by the physician.
Major finding: Itch severity had a weak positive correlation with objective Scoring Atopic Dermatitis (rho (ρ) 0.44; 95% CI 0.39-0.48), Eczema Area and Severity Index (ρ 0.41; 95% CI 0.36-0.46), and Investigator Global Assessment (ρ 0.46; 95% CI 0.42-0.51) scores, but a strong positive correlation with Patient Global Assessment score (ρ 0.68; 95% CI 0.65-0.71), Patient-Oriented Eczema Measure sum score (ρ 0.66; 95% CI 0.63-0.69), and Dermatology Life Quality Index score (ρ 0.61; 95% CI 0.57-0.65).
Study details: This study analyzed the data of 1134 adult patients with moderate-to-severe AD from the multicenter prospective TREATgermany registry, of which 1121 had provided data on their itch.
Disclosures: TREATgermany is sponsored by AbbVie Deutschland GmbH & Co. KG, Galderma S.A., and others. Some authors reported ties with various organizations, including TREATgermany sponsors.
Source: Weisshaar E et al. Itching in atopic dermatitis: Patient- and physician-reported outcomes in the German atopic dermatitis registry TREATgermany. Acta Derm Venereol. 2023;103:adv00854 (Jan 23). Doi: 10.2340/actadv.v103.4426